Effects of agmatine on chlorpromazine-induced neuronal injury in rat by Dejanović, Bratislav et al.
Effects of agmatine on chlorpromazine-induced neuronal injury in rat
Bratislav Dejanovic1, Vesna Vukovic-Dejanovic2, Milica Ninkovic3, Irena Lavrnja4, 
Ivana Stojanovic5, Milos Pavlovic6, Vesna Begovic7, Dusko Mirkovic8, Ivana Stevanovic3
1University of Defence, Military Medical Academy, Faculty of Medicine MMA, 
Institute of Medical Biochemistry, Belgrade, Serbia
2Insitute for Rehabilitation, Belgrade, Serbia
3University of Defence, Military Medical Academy, Faculty of Medicine MMA, 
Institute for Medical Research, Belgrade, Serbia
4Institute for Biological Research “Sinisa Stankovic”, Belgrade, Serbia
5University of Nis, Faculty of Medicine, Institute for Biochemistry, Nis, Serbia
6Faculty of Veterinary Medicine, Department of Obstetrics, Belgrade, Serbia
7University of Defence, Military Medical Academy, Faculty of Medicine MMA, Clinic for Infectious and 
Tropical Disease, Belgrade, Serbia
8Faculty of Pharmacy, Department of Medicinal Biochemistry, Institute for Medical Biochemistry Clinical 
Centre of Serbia, Belgrade, Serbia
Received February 24, 2017
Accepted May 15, 2018
Abstract 
This study was aimed to study the potentially beneficial effects of agmatine on oxidative/
nitrosative stress development in the brain of Wistar rats during subacute chlorpromazine 
treatment. The animals were divided into control (0.9% saline), chlorpromazine (38.7 mg/kg b.w.), 
chlorpromazine+agmatine (agmatine 75 mg/kg b.w. immediately after chlorpromazine, 38.7 mg/
kg b.w. i.p.) and agmatine (75 mg/kg b.w.) groups. All the tested substances were administered 
intraperitoneally for 15 consecutive days and the rats were sacrificed by decapitation on day 15. 
Subacute administration of chlorpromazine resulted in increased lipid peroxidation, nitric oxide 
concentration and superoxide anion production, while completely damaging the antioxidant 
defence system in the cerebral cortex, striatum, and hippocampus. However, the combined 
treatment with chlorpromazine and agmatine significantly attenuated the oxidative/nitrosative 
stress indices and restored the antioxidant capacity to the control values in all of the examined 
brain regions. Western blot analysis supported biochemical findings in all groups, but the most 
notable changes were found in the hippocampus. Our results suggest potentially beneficial effects 
of agmatine, which may be useful in the modified antioxidant approach in chlorpromazine-
therapy. 
Antioxidant defence, brain, oxidative stress
Antipsychotics are used extensively in the treatment of schizophrenia and other affective 
disorders (Saha et al. 2016). Chlorpromazine (CPZ) is a typical antipsychotic drug that 
may have side effects during treatment (Li  et al. 2008), partially mediated by oxidative 
stress (Dejanovic et al. 2016). 
Oxidative stress (OS) and the products of lipid peroxidation (LPO) are implicated in 
the pathophysiology of various neurological disorders (Cobb and Cole 2015). Typical 
antipsychotics have been shown to increase OS by altering the levels of antioxidant en-
zymes and causing oxidative injury, particularly LPO in the brain (Parikh et al. 2003). 
Thiobarbituric acid reactive substances (TBARS) are the markers of LPO that significantly 
increase after CPZ poisoning (Safhi  2016). Nitric oxide (NO) is produced by the action of 
the isoenzymes of NO synthases (NOS) and it may react with thiol groups in amino acids 
and proteins to form relatively stable nitroso-thiols (Gergel and Cederbaum 1996). 
Biological systems have evolved complex protective strategies against free radical 
toxicity. These antioxidant defence mechanisms include enzymes that scavenge reactive 
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oxygen and nitrogen species (ROS/RNS), such as catalase (CAT), glutathione peroxidase 
(GPx), superoxide dismutase (SOD), but also nonenzymatic biomolecules: glutathione 
(GSH), vitamins C and E, uric acid (Dringen  2005). The key antioxidant enzyme, SOD, 
catalyses the conversion of superoxide anion (O2
•-) to hydrogen peroxide (H2O2), which 
in turn can form the highly reactive hydroxyl radical (OH•). The other two antioxidant 
enzymes, CAT and GPx, convert H2O2 to water (Parikh et al. 2003). Glutathione, a radical 
scavenger, is converted to oxidized glutathione (GSSG) by the action of GPx and converted 
back to GSH by the enzyme glutathione reductase (GR). 
The present study was aimed to study the potentially beneficial effect of agmatine – AGM 
(4-aminobutyl) guanidine, on OS development during CPZ toxicity. Agmatine is an amine 
that is formed by decarboxylation of L-arginine by the enzyme arginine decarboxylase and 
hydrolysed by the enzyme agmatinase to putrescine (Regunathan et al. 1996). It emerges 
as neuromodulator and a promising agent to manage diverse central nervous system 
disorders by modulating the NO pathway, glutamate N-methyl-D-aspartate (NMDA) 
receptors and OS/nitrosative stress (NS). Also, AGM has recently been shown to have 
neuroprotective effects due to its antioxidant properties (Chai  et al. 2016).
Based on this background, the aim of our study was to investigate the role of ROS/RNS 
and the efficiency of antioxidant defence in rat selective vulnerable brain regions (VBRs), 
such as the cerebral cortex, striatum, and hippocampus in subacute CPZ intoxication after 
AGM treatment.
Materials and Methods
Animals
Consent of the Ethics Committee for the welfare of experimental animals No. 323-07-03937/2016-05/7 
is obtained from Ministry of Agriculture and Environmental Protection – Veterinary Directorate. Adult male 
Wistar rats (weighing of 200–250 g b.w.) were kept in cages under standardized housing conditions (ambient 
temperature: 23 ± 2 °C, relative humidity: 55 ± 3% and a light/dark cycle: 13/11 h) and had free access to standard 
laboratory pellet food and tap water. The adaptation period to the laboratory conditions was two weeks and all the 
subsequent procedures were performed between 9:00 h and 13:00 h. 
Experimental procedure
The experiment was accomplished with the following four experimental groups, which received different 
testing substances intraperitoneally (i.p.) at the volume of 20 μl per 100 g b.w. for 15 consecutive days: the 
control group (C, 0.9% saline), n = 10; the CPZ group (CPZ-HCl 38.7 mg/kg b.w.), n = 10; the CPZ+AGM group 
(AGM, 75 mg/kg b.w. i.p., immediately after CPZ-HCl administration, 38.7 mg/kg b.w.), n = 10; and the AGM 
group (AGM, 75 mg/kg b.w. i.p.), n = 10. The animals were sacrificed by decapitation 15 days after the start of 
the treatment. The animals’ brains were excised and stored at -20 °C.
Measurement of oxidative/nitrosative status indicators 
The brain structures – cerebral cortex, striatum and hippocampus were dissected on ice, and 0.1 g of each tissue 
slice was transferred into sucrose medium (0.25 M/l sucrose, 0.1 mM/l EDTA in 50 mM K-Na phosphate buffer, pH 
7.2). Homogenization was performed on ice by a homogenizer (Tehtnica, Zelezniki, Slovenia) at 800 rotations/min. 
The homogenates were centrifuged (1000 × g, 15 min, 4 °C), the precipitates were redispersed in sucrose medium, 
centrifuged (2500 × g, 30 min, 4 °C) and the obtained precipitates were redispersed in 1.5 ml of deionized water. 
After that, the samples were centrifuged again (2000 × g, 15 min, 4 °C) and the supernatants (crude mitochondrial 
fractions) were stored at -70 °C (Gurd  et al. 1974). Lipid peroxidation in VBRs was measured as TBARS production 
as described by Girotti  et al. (1991). Data were expressed as nmol per mg of proteins.
After deproteinization the production of NO was evaluated by measuring nitrite and nitrate concentrations (NO2 
+ NO3). Nitrates were previously transformed into nitrites (by cadmium reduction), which were assayed directly 
spectrophotometrically (Pharmacia Biotech Ultrospec 2000) at 492 nm, using the colorimetric method of Griess 
(Griess reagent: 1.5% sulfanilamide in 1 mol HCl plus 0.15% N-(1-naphthyl)ethylendiamine dihydrochloride 
in deionized water) (Navarro-Gonzalez  et al. 1998). The results were expressed as nmol per mg of proteins.
Superoxide anion radical (O2
•-) content was determined through the reduction of nitroblue-tetrazolium (NBT) 
in the alkaline nitrogen saturated medium. Kinetic analysis was performed at 550 nm (Auclair and Voisin 
1985). The results were expressed as nmol of reduced NBT per min per mg of proteins.
Superoxide dismutase (EC 1.15.1.1.; SOD) activity was measured spectrophotometrically, as an inhibition 
of epinephrine spontaneous auto-oxidation at 480 nm. The kinetics of sample enzyme activity was followed in 
a carbonate buffer (50 mmol, pH 10.2), containing 0.1 mmol EDTA, after the addition of 10 mmol epinephrine 
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(Sun and Zigman  1978). Data were expressed as microkatal (μkat) per mg of proteins.
Catalase activity (CAT) was determined by the spectrophotometric method. Ammonium molybdate forms a 
yellow complex with H2O2 and is suitable for measuring CAT activity in the tissue (Góth  1991). Kinetic analysis 
was performed at 405 nm. The unit of CAT activity was defined as the number of H2O2 micromols reduced per 
min (µmol H2O2/min). Data were expressed as μkat per mg of proteins.
The total glutathione (GSH+1/2GSSG, in GSH equivalents) content was determined using the DTNB-GSSG 
reductase recycling assay. The rate of formation of 5-thio-2-nitrobenzoic acid (TNB), which is proportional to the 
total GSH concentration, was followed spectrophotometrically at 412 nm (Anderson 1986). The results were 
expressed as nmol per mg of proteins. 
The assessment of GPx activity was determined using a commercial kit (Randox Laboratories Ltd.). 
GPx catalyses the oxidation of reduced GSH by cumene hydroperoxide. In the presence of reduced GR and 
nicotinamide adenine dinucleotide phosphate-reduced form (NADPH), the GSSG is immediately converted to the 
reduced form with a concomitant oxidation of NADPH into NADP+. The decrease in absorbance is measured at 
340 nm (Randox 1996). The unit of enzyme activity of GPx is defined as the number of micromols of NADPH 
oxidized per min (µmol NADPH/min). Data were expressed as μkat per mg of proteins.
The method for GR activity determination is based on the ability of GR to catalyse the reduction of GSSG 
to GSH by the oxidation of the coenzyme NADPH into NADP+ (Freifelder 1976). In the reaction, we used 
100 mmol nicotinamide adenine dinucleotide (NAD) as standard. The unit of enzyme activity is defined as the 
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Fig. 1A-C. Oxidative/nitrosative status after appropriate treatment: A) thiobarbituric acid reactive supstances 
(TBARS; nmol/mg proteins), B) nitrite and nitrate concentrations (NO2 + NO3; nmol/mg proteins) and C) 
superoxide anion radical (O2
•-, nmol red NBT/min//mg proteins) in the rat cerebral cortex, striatum and 
hippocampus from control (C), chlorpromazine (CPZ), chlorpromazine + agmatine (CPZ+AGM) and agmatine 
(AGM) groups 15 days after appropriate treatment. Bars in the graph represent mean ± STDEV from 6 animals 
of each group. The labels of significance: compared to *control group (C) and #chlorpromazine-group (CPZ). 
Statistical significance was considered at *,#P < 0.05, **,##P < 0.01 and  ***,###P < 0.001 (One Way ANOVA, 
Dunnett’s test).
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Fig. 2A-E. Antioxidant status after appropriate 
treatment: A) superoxide dismutase activity (SOD); 
μkatal (μkat)/mg proteins, B) catalase activity (CAT); 
μkatal (μkat)/mg proteins, C) GSH content (nmol/mg 
proteins), D) glutathione peroxidase activity (GPx); 
μkatal (μkat)/mg proteins, and E) glutathione reductase 
activity (GR); μkatal (μkat)/mg proteins in the rat 
cerebral cortex, striatum and hippocampus from control 
(C), chlorpromazine (CPZ), chlorpromazine + agmatine 
(CPZ+AGM) and agmatine (AGM) groups, 15 days 
after appropriate treatment. Bars in the graph represent 
mean ± STDEV from 6 animals of each group. The labels 
of significance: compared to *control group (C) and 
#chlorpromazine-group (CPZ). Statistical significance 
was considered at *,#P < 0.05, **,##P < 0.01 and 
***,###P < 0.001 (One Way ANOVA, Dunnett’s test).
number of micromols of NADPH oxidized per min (µmol NADPH). The results were expressed as μkat per mg 
of proteins.
The Lowry method was used for protein measurement in rat VBRs (Lowry et al. 1951).
Western blot analysis
After decapitation, the brains from three animals from each group were dissected and pooled. The selected 
tissue was homogenized with a hand-held pestle in sodium dodecyl sulphate (SDS) sample buffer (10 ml/mg), 
which contained a cocktail of proteinase and phosphatase inhibitors (Harry  et al. 1996). The electrophoresis 
samples were heated at 100 °C for 5 min and loaded onto 10% SDS-polyacrylamide gels with standard Laemmli 
solutions (Bio-Rad Laboratories, CA, USA). The proteins were electroblotted onto a polyvinylidene difluoride 
membrane. The membranes were placed in a blocking solution for 1 h, and incubated overnight under gentle 
agitation with primary antibody mouse anti-Glial fibrillary acidic protein (GFAP) (1:5000 Abcam, Cambridge, 
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UK) and mouse anti-β-actin (1:1000; Sigma, St Louis, MO, USA). Bound primary antibodies were detected with 
a horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibody (1:5000; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA). Immunoreactive bands were visualized on X-ray films (Kodak, Rochester, NY, USA), 
using chemiluminescence. Optical densities of immunoreactive bands from 4 independent blots were calculated 
in the ImageQuant GE (Healthcare, Chicago, USA). The densities of GFAP and β-actin immunoreactive bands 
were quantified with background subtraction. Squares of identical sizes were drawn around each band to measure 
density, and background near that band was subtracted. For each blot, optical densities were normalized against 
β-actin levels.
Statistical analysis 
One-way ANOVA and post hoc Dunnett’s C tests were used (software GraphPad Prism, version 5.01, La 
Jolla, California, USA) for statistical data analysis. Values were presented as means ± standard deviation (SD). 
Differences were considered significant at P < 0.05. 
Results
The CPZ application increased NO2 + NO3 concentration in each brain structure (P < 
0.05), as well as TBARS concentration (P < 0.05; P < 0.05; P < 0.01) and O2•- production 
(P < 0.01; P < 0.01; P < 0.001) in the rat cerebral cortex, striatum and hippocampus, 
respectively, compared to the C values. However, CPZ + AGM treatment decreased 
the TBARS concentration (P < 0.05; P < 0.01; P < 0.01) and O2•- production (P < 0.01; 
P < 0.001; P < 0.01) in the rat cerebral cortex, striatum and hippocampus, respectively, 
compared to the controls (Fig. 1A–C).
The application of CPZ significantly increased the SOD activity in the hippocampus 
(P < 0.05) and decreased the enzyme activity in the striatum (P < 0.05) compared to the 
controls (Fig. 2A). The CAT activity was significantly increased in the cerebral cortex 
(P < 0.05), and decreased in both the striatum (P < 0.05) and the hippocampus (P < 0.05) 
compared to group C (Fig. 2B). The CPZ injection completely decreased and damaged 
the GPx activity (in each brain structure, P < 0.05), as well as the GSH content (P < 
0.05; P < 0.01; P < 0.01) and GR activity (P < 0.05; P < 0.01; P < 0.05) in the cerebral 
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Fig. 3A-C. Quantitative immunoblot detection of glial fibrillary acidic protein (GFAP) protein levels in A) cerebral 
cortex, B) striatum and C) hippocampus isolated from control (C), chlorpromazine (CPZ), chlorpromazine + 
agmatine (CPZ+AGM) and agmatine (AGM) groups, 15 days after the treatment. Bars represent mean GFAP 
protein abundance (± STDEV) from three independent determinations expressed relative to β-actin. Significance 
level is shown in the graph (*P < 0.05 vs. C-group; #P < 0.05 vs. CPZ-group), which is accompanied by a 
representative immunoblot. 
cortex, striatum and hippocampus, respectively, compared to the controls (Fig. 2C–E). 
The treatment with AGM applied together with CPZ decreased the activity of SOD in the 
cerebral cortex (P < 0.01) and hippocampus (P < 0.001) compared to group CPZ (Fig. 2A). 
However, CPZ + AGM treatment increased both the CAT and GPx activities in each brain 
structure (P < 0.05), as well as the GSH content (P < 0.01; P < 0.05; P < 0.01) and GR 
activity (P < 0.05; P < 0.05; P < 0.01) in the rat cerebral cortex, striatum and hippocampus, 
respectively, compared to the controls (Fig. 2B–E).
To assess the pattern of GFAP protein expression following CPZ-induced brain injury in 
rats and after the AGM treatment, the brains were isolated 15 days post injury. Immunoblot 
analysis showed that GFAP was present in all examined VBRs as a single band with a 
molecular mass of about 50 kDa (Fig. 3A–C). The CPZ injection increased GFAP 
expression in the hippocampus compared to the physiological control and decreased its 
expression in group CPZ+AGM in respect to the CPZ-induced injury. 
Discussion
Oxidative stress and LPO with pursuing changes of the antioxidant defence capacity may 
be responsible for one of the molecular mechanisms of CPZ intoxication in the brain tissue. 
Based on our results, we found that AGM has protective effects on the indices of OS/NS in 
VBRs, and, especially, on the antioxidant defence system.
With regard to the neuroanatomical organization of the brain and selective vulnerability of 
the examined structures on toxic CPZ effects, there is spatial spreading of damage induced 
by the drug. It means that biochemical changes were found in the cerebral cortex, striatum, 
and hippocampus. Our results indicate that CPZ might disturb the balance between ROS/
RNS production and lead to brain damage through the process comprising the oxidative 
modification of lipids, which results in a progressive loss of membrane fluidity, reduced 
membrane potential and increased permeability to ions, such as Ca2+ (Bastianetto et al. 
2006). The increase, expressed in percentage of the control was: in the cerebral cortex 
(TBARS by 48%, NO2 + NO3 by 50%, O2•- by 28%), striatum (TBARS by 38%, NO2 + NO3 
by 34%, O2•- by 33%), as well as in the hippocampus (TBARS by 45%, NO2 + NO3 by 35%, 
O2•- by 45%) (Fig. 1A–C). The significant increase in NO level after CPZ injection (Fig. 
1B) indicates that NS may play a significant role in CPZ-induced brain injury (Lores-
Arnaiz et al. 2004). The importance of RNS in CPZ-induced toxicity was demonstrated 
in different studies which confirmed that low level of NO exerted protective effects on 
neurons, but high level of NO could be damaging due to the reaction of NO with O2•- and 
the peroxinitrite production (Bosch-Morell et al. 2002; Lores-Arnaiz et al. 2004).
Reactive oxygen species have been shown to be part of both intracellular signalling 
and intracellular communication, the processes involved in maintaining homeostasis, but 
when excessively produced in vivo, they are deleterious to integral components of the cell 
and cause their dysfunctions (Rojczyk et al. 2015). Some experimental data indicate that 
ROS-mediated LPO, protein oxidation and oxidative alterations to nucleic acids are crucial 
events of unfavourable actions of ROS (Juranek and Bezek 2005). The increased O2•- 
production along with decreased GPx activity (Fig. 2D) in all VBRs after CPZ injection 
suggest damage of the cell antioxidant system.
Also, we previously demonstrated that acute administration of CPZ increased the 
production of free radicals and affected the antioxidant capacity in the rat brain (Dejanovic 
et al. 2015, 2016). The results presented here indicate that subacute CPZ application 
damaged the antioxidant defence system in all examined VBRs (Fig. 2). Striatal spiny 
neurons serve as a major anatomical locus for the relay of the cortical information flow 
through the basal ganglia. Subacute administration of CPZ, which resulted in an increase 
of O2•- production and a decrease of SOD activity in the striatum, suggested the presence 
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of OS. Also, our study which demonstrated that CPZ induced a decrease in both SOD and 
CAT activities and an increase in TBARS concentrations in the striatum, was consistent 
with other studies of CPZ toxicity (Bishnoi et al. 2007). An inadequate free radical 
sequestration is the consequence of reduced antioxidant enzyme activities. Increased 
free radical concentrations lead ultimately to oxidative injury of numerous biomolecules, 
including these enzymes, as well. Reduced CAT activity might be explained by a reduced 
amount of H2O2, the substrate of CAT (Djukic et al. 2012). However, the increased SOD 
activity along with increased TBARS concentration in the hippocampus can be explained 
by peroxidation in the destruction of membrane lipids.  
Glutathione, as a multifunctional, intracellular nonenzymatic antioxidant is the major 
component of intracellular regulation of the redox state which provides the first line of 
defence against oxidative injury (Jorgacevic et al. 2013). Also, GSH is an important 
substrate and cofactor in drug metabolism (Nemmiche et al. 2007). Its role in protecting 
cells from the toxic effects of free radicals and other components with electrophilic 
properties is reflected in the antioxidant effect, because it neutralizes ROS within cells 
directly or through the GPx/GSH cycle (Lopert and Patel 2014). Decreased GSH content 
(Fig. 2C) in inverse proportion to the NO level (Fig. 1B) can be explained by oxidation 
of GSH within free radical neutralization, as well as its lower synthesis, resulting from 
decreased production of cysteine as the limiting GSH precursor. It has been previously 
known that CPZ is oxidized into CPZ cation radical, which strongly stimulates oxidation 
in the presence of H2O2 (Hu and Kulkarni 2000). It has been also shown that the 
different peroxidases and methaemoglobin catalyse single electron oxidation of CPZ into 
a biologically active CPZ cation radical. This radical is highly reactive and can interact 
with GSH when CPZ cation radical leads to the formation of glutathione thiol radical 
cation of CPZ, which is responsible for both pharmacological efficacy and toxic effects of 
this drug. Since it is known that CPZ affects the formation of free radicals, it would mean 
that this drug can initiate OS in the brain. Not surprisingly, we found decreased both the 
GSH content and the GR activity 15 days after CPZ injection (Fig. 2C, E). Other indices 
confirmed that OS processes were operative even at subacute CPZ administration. 
It is known that AGM is an endogenous neuromodulator with the potential for new 
drug development (Piletz et al. 2013). The combined treatment with CPZ and AGM 
significantly attenuated the OS indices in all examined VBRs (Fig. 1). The beneficial 
effect of AGM could be related to its ability to inhibit inducible form of NOS or to block 
NMDA receptors and/or voltage-dependent Ca2+ channels (Reis  et al. 1998). Blockade 
of either of these signalling proteins would likely be protective. A possible explanation 
for the unchanged NO level and the decreased TBARS concentration might be that NO 
acts as a ROS scavenger, protects cells from LPO and consequently prevents progressive 
increase of the TBARS level. These results indicate that LPO might have a more important 
role in protection after AGM administration in CPZ toxicity than NS. Also, the reduced 
O2•- production confirms the protective effect of AGM and can be explained by its total 
antioxidant potential.
Additionally, the CPZ+AGM treatment which caused the significant decrease in the TBARS 
concentration, suggested the activation of the antioxidant system, resulting in an aggressive 
oxidative mechanism blockade initiated by CPZ application. Our study demonstrated the 
massive increase of enzymatic (CAT, GPx) and nonenzymatic (GSH) antioxidant capacity, 
showing adequate antioxidant cell defence against neuronal injuries (Fig. 2).
The neuroprotective roles of AGM were confirmed by the improvement of the OS status 
development indicators (decreased TBARS and increased GSH concentration). Also, the 
increased GR activity in the CPZ+AGM group indicated the importance of maintaining the 
content of GSH at the level necessary to achieve the antioxidant role (Fig. 2E). In fact, the 
increased GR activity sustained GSH levels by extracellular reduction of GSSG. 
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Based on the electrophoretic profiles of the GFAP molecules, an indicator of reactive 
astroglial changes to neuronal damage in VBRs, we found clear differences in the levels of 
expression of the protein, which were most pronounced in the hippocampus after subacute 
CPZ treatment (Fig. 3C). Decreased GFAP expression 15 days after the CPZ+AGM 
treatment could indicate reduced astrogliosis in the hippocampus with a region-specific 
decrease in GFAP expressing cell profiles.    
In conclusion, our data revealed that ROS/RNS were included in CPZ-induced 
neurotoxicity, resulting in both temporal and spatial spreading of damage to the VBRs, 
so that AGM could have potentially neuroprotective effect and partially ameliorated 
oxidative/nitrosative damage after CPZ toxicity. Explanation of damage mechanisms after 
CPZ-induced neurotoxicity can be of great importance for both veterinary and human 
medicine in preventing altered functional and structural conditions in the brain tissue. The 
use of AGM can improve health and physical capability as well as lead to better recovery 
after poisoning.
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